Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?

Company Overview - Argenx SE (ARGX) shares increased by 4.4% to close at $606.39, following a notable trading volume, contrasting with a 4% loss over the past four weeks [1] - The stock's rally is linked to growing optimism regarding its marketed product, Vyvgart Hytrulo (efgartigimod), which is approved for treating adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [2] Product Developments - The FDA has recently approved a new self-injection option for Vyvgart Hytrulo using a prefilled syringe for the aforementioned indications [2] - Argenx is also exploring the use of efgartigimod in various serious autoimmune diseases [2] Financial Performance Expectations - The company is projected to report quarterly earnings of $2.20 per share, reflecting a year-over-year increase of 311.5% [3] - Expected revenues are $790.36 million, which is a 91.6% increase compared to the same quarter last year [3] Earnings Estimate Revisions - The consensus EPS estimate for Argenx has been revised 1.6% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - The stock currently holds a Zacks Rank of 3 (Hold) [4] Industry Context - Argenx is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Viridian Therapeutics, Inc. (VRDN), saw a 10.7% increase in its stock price, closing at $13.30, despite a -24.5% return over the past month [4] - Viridian Therapeutics has an unchanged consensus EPS estimate of -$0.95, representing a -20.3% change from the previous year [5]